Immune dysregulation, oxidative stress, neuroinfl ammation and apoptotic cell death are all potential parts of ALS pathophysiology (8). Thus, if these purported actions of Spirulina are accurate, there is at least a theoretical basis for its use in ALS.
What are the data for use of Spirulina in ALS?
In the recent paper, ' Neuroprotective Effect of Spirulina in a Mouse Model of ALS ' , authors Svitlana Garbuzova-Davis and Paula Bickford test their hypothesis that adding Spirulina to the diet can slow down or stop motor neuron degeneration in the mutant SOD1 mouse model of ALS (9). Mutant SOD1 mice were given a diet supplemented with 0.1% Spirulina powder for 10 weeks, starting at fi ve weeks of age, and compared to mutant SOD1 mice on an unsupplemented diet. At 15 weeks of age, the authors 1) weighed the mice; 2) assessed the extent of the hindlimb splay refl ex, a widely used assay of motor strength; 3) measured the mRNA levels of selected cytokines (typically involved in infl ammation); and 4) sacrifi ced the animals and used histological techniques to observe motor neuron degeneration and glial cell proliferation. The mice on the diet with Spirulina gained more weight than the non-treated mice, had a slightly greater splay ability in the right hindlimb but not the left, had reduced cytokine levels in a few regions of the brain and spinal cord, and displayed fewer degenerating neurons and reactive glia in sample histological sections of the spinal cord. The authors concluded that " Spirulina slowed the onset of motor symptoms and disease progression " and that " a Spirulina supplemented diet may have future clinical benefi t in treating ALS as an alternative or adjunctive therapy " .
At best, this paper can be considered an introduction to the authors ' hypothesis. It is not clear that the conclusions are supported by the authors ' data. Spirulina was associated with improved weight gain, but it is no way proven that this was due to an effect Now 22 months old, ALSUntangled (www. alsuntangled.org) has 315 twitter followers. Our NING consists of 72 ALS clinician scientists from across seven countries, participating in more than 30 active discussions. New discussions opened since our last publication include BuNaoGao (BNG), Dean Kraft, Dr. Shahriar Vaziritabar and ' The Healing Code Solution ' . We have published eight investigations on nine different alternative and off-label treatment options and are collaborating with Quackwatch (www.quackwatch.org), Patients Like Me (www. patientslikeme.com) and ALS Worldwide (www. alsworldwide.org). At the request of multiple PALS, we here investigate the use of a blue-green algae product called Spirulina as a treatment for ALS.
What is Spirulina?
According to its website, Spirulina is a commercially cultivated, dried form of the cyanobacterium Arthrospira platensis (1) . Arthrospira are a specifi c kind of blue-green algae from alkaline lakes; the high pH in such lakes supposedly prevents other algae from growing and contaminating the product. It is said to consist mainly of protein, pro-vitamin A, mixed carotenoids, phycocyaninin, chlorophyll and gamma linoleic acid (1) .
What is the rationale for using Spirulina in ALS?
Promoters claim that Spirulina has nutritional benefi ts, modulates immune function and has " strong antioxidant and anti-infl ammatory activities " (1) . Spirulina extract appears to protect mouse embryo fi broblasts from DPPH-or ABTS-induced apoptotic cell death, although the effect seen is less than that obtained with vitamin C (2). Small animal and human studies suggest that Spirulina extracts may lower cholesterol (3), alter interleukin and interferon levels (3, 4) , increase SOD1 activity (3, 5) , and enhance natural killer cell (4,6) and macrophage phagocytic activity (7). on motor neurons. It may simply be that Spirulinatreated mice took in more calories. In this context, the improved nutrition in Spirulina-treated animals might account for any effect on slowed disease progression, rather than a more exotic immunomodulatory or anti-oxidant mechanism. The paper does not provide data to suggest that there was slowing of onset of motor symptoms, because it did not report onset of motor symptoms. The unilateral effect on hindlimb splay is odd; why would a true effect be seen only on one side? The authors did not count motor neurons to see if in fact fewer were degenerating; rather, they qualitatively looked at the slides to obtain an impression. Finally, they ended the experiment when the mice were 105 days old, essentially preventing determination of whether the treated mice actually survived longer than non-treated mice (the SOD1 mutant mice live to about 130 days). The authors acknowledged these defi cits in the paper, and indicated their intent to carry out follow-up experiments. However, one of the authors of this paper is a cofounder of a company that sells nutritional supplements; this creates a potential confl ict of interest and possible source of bias when reporting subjective measurements as was done here.
Even if the authors can someday show that they are able to use Spirulina to delay onset or slow progression in this animal model, it is not clear what this would mean for patients with ALS. It is not currently possible to start treatment in patients before the clinical onset of their motor dysfunction. Furthermore, a number of immunomodulatory and anti-oxidant treatments have already been shown to slow progression in the SOD1 mouse, and have had no similar effect on patients with ALS.
Within the Patients Like Me online community, six members with ALS report taking any form of blue-green algae; two report taking the brand Spirulina and one reports taking the brand Pure Planet Hawaiian Spirulina. Dosages taken ranged from 3 mg to 3000 mg daily, and durations of therapy ranged from three months up to two years or more. Compliance was high, with members reporting either " always " or " usually " taking their selected regimen. No members reported any effi cacy or side-effects. All six have stopped taking blue-green algae, with four stating they stopped due to lack of effi cacy and two stating they stopped due to cost. Reported out-ofpocket costs ranged from $ 50 to $ 200 per month.
What are the potential problems with Spirulina for ALS?
Some types of blue-green algae contain toxins (10); these include microcystins that are toxic to the liver, heavy metals, neurotoxic alkaloids, and the chemical BMAA, which may even be an environmental trigger for ALS (11). Vendors of Spirulina state that their product is free of most or all of these toxins, but assurance of this supplement is up to the manufacturer or vendor, unlike FDA regulated pharmaceuticals. Even if it is toxin free, there are other real and theoretical and safety concerns related to the use of Spirulina in patients with ALS. One website reports possible adverse reactions to Spirulina including upset stomach, diarrhea, and rash and that there is a potential for more serious allergic reactions (12) . Spirulina contains pro-vitamin A, and too much vitamin A can be toxic. Worse lipid profi les may be associated with slower ALS progression (13); thus, the purported lipid-lowering effect of Spirulina could theoretically accelerate ALS progression. Similarly, decreasing macrophage phagocytic activity may slow ALS progression and is now being pursued in treatment trials (14) ; by activating macrophage phagocytic activity Spirulina could theoretically accelerate ALS progression.
Conclusion
At this time, ALSuntangled fi nds no evidence that Spirulina is effective for ALS and there appear to be real and theoretical toxicities that patients with ALS may encounter with it. Until better effi cacy and safety studies are published, we do not support the use of Spirulina in patients with ALS.
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